Cannabis and Cannabinoids on Treatment of Inflammation: A Patent Review

Author(s): Pedro Modesto Nascimento Menezes, Emanuella Chiara Valença Pereira, Maria Eduarda Gomes da Cruz Silva, Bismarques Augusto Oliveira da Silva, Luiz Antonio Miranda de Souza Duarte Filho, Tarcísio Cícero de Lima Araújo, Kátia Simoni Bezerra Lima, Fabrício Souza Silva, Larissa Araújo Rolim*.

Journal Name: Recent Patents on Biotechnology

Volume 13 , Issue 4 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: The inflammatory process is a physiological response to a vast number of harmful stimulus that takes place in order to restore homeostasis. Many drugs used in pharmacotherapy are effective to control inflammatory responses, however, there is a range of adverse effects attributed to steroidal and non-steroidal anti-inflammatory drugs (NSAIDs). In this sense, herbal medicine and derivatives have gained more attention because of their effectiveness and safety, showing the importance of medicinal plants, especially the Cannabis genus and the cannabinoid derivatives.

Objective: The aim of this prospection was to identify data related to patents involving Cannabis and cannabinoids for the treatment of inflammation.

Methods: To do so, a search for patents was conducted to evaluate the anti-inflammatory activity of Cannabis and cannabinoids. Four specialized databases for patent research were consulted using the terms "cannabis", "cannabidiol", "cannabinoids" and "THC" associated with "inflammation".

Results: A total of 370 patents were found, of which 17 patents met the inclusion criteria. Although reports show synergistic effects of the plant components, patents involving Cannabis and cannabinoids focus on isolated substances (CBD e THC).

Conclusion: However, patents related to Cannabis and cannabinoids are promising for future use of the plant or its derivatives on the treatment of inflammation.

Keywords: Hemp, inflammation disease, marijuana, technological prospecting, therapeutic, herbal medicine.

[1]
Grotenhermen F, Müller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int 2012; 109(29-30): 495-501.
[2]
Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 2006; 105(1-2): 1-25.
[3]
Warf B. High points: An historical geography of cannabis. Geogr Rev 2014; 104(4): 414-38.
[4]
Brand EJ, Zhao Z. Cannabis in Chinese medicine: are some traditional indications referenced in ancient literature related to cannabinoids? Front Pharmacol 2017; 8: 108.
[5]
Perrot S. Cannabis: the analgesic and antiinflammatory medication of the future? Joint Bone Spine 2004; 71(1): 7-8.
[6]
Fischedick JT, Hazekamp A, Erkelens T, Choi YH, Verpoorte R. Metabolic fingerprinting of Cannabis sativa L., cannabinoids and terpenoids for chemotaxonomic and drug standardization purposes. Phytochemistry 2010; 71(17-18): 2058-73.
[7]
Casajuana KC, López-Pelayo H, Balcells-Olivero MM, Colom J, Gual A. Psychoactive constituents of cannabis and their clinical implications: a systematic review. Adicciones 2018; 30(2): 140-51.
[8]
Gould J. The cannabis crop. Nature 2015; 525(7570): S2-3.
[9]
Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2006; 45(1): 50-2.
[10]
Shang VC, Kendall DA, Roberts REΔ. 9-Tetrahydrocannabinol reverses TNFα-induced increase in airway epithelial cell permeability through CB2 receptors. Biochem Pharmacol 2016; 120: 63-71.
[11]
Murray RM, Quigley H, Quattrone D, Englund A, Di Forti M. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry 2016; 15(3): 195-204.
[12]
Gul W, Gul SW, Chandra S, Lata H, Ibrahim EA, ElSohly MA. Detection and quantification of Cannabinoids in extracts of Cannabis sativa roots using LC-MS/MS. Planta Med 2018; 84(4): 267-71.
[13]
Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 2011; 163(7): 1344-64.
[14]
Bergamaschi MM, Queiroz RHC, Zuardi AW, Crippa JA. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 2011; 6(4): 237-49.
[15]
Russo EB, Jiang HE, Li X, et al. Phytochemical and genetic analyses of ancient cannabis from Central Asia. J Exp Bot 2008; 59(15): 4171-82.
[16]
Haney M, Rabkin J, Gunderson E, Foltin RW. Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology (Berl) 2005; 181(1): 170-8.
[17]
Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009; 34(3): 672-80.
[18]
Barnes MP. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother 2006; 7(5): 607-15.
[19]
Agência Nacional de Vigilância Sanitária Resolução da Diretoria Colegiada - RDC n° 66 Brasil: ANVISA;( RDC Nº 66) 2016.
[20]
Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem 2009; 1(7): 1333-49.
[21]
Turcotte C, Chouinard F, Lefebvre JS, Flamand N. Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. J Leukoc Biol 2015; 97(6): 1049-70.
[22]
Ahmed AU. An overview of inflammation: mechanism and consequences. Front Biol 2011; 6(4): 274-81.
[23]
Ashley NT, Weil ZM, Nelson RJ. Inflammation: mechanisms, costs, and natural variation. Annu Rev Ecol Evol Syst 2012; 43: 385-406.
[24]
Vergnolle N. The inflammatory response. Drug Dev Res 2003; 59(4): 375-81.
[25]
Kotas ME, Medzhitov R. Homeostasis, inflammation, and disease susceptibility. Cell 2015; 160(5): 816-27.
[26]
Rainsford KD. Anti-inflammatory drugs in the 21st century. Subcell Biochem 2007; 42: 3-27.
[27]
Fokunang CN, Fokunang ET, Frederick K, et al. Overview of non-steroidal anti-inflammatory drugs (NSAIDs) in resource limited countries. MOJ Toxicol 2018; 4(1): 5-13.
[28]
Ong CKS, Lirk P, Tan CH, Seymour RA. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res 2007; 5(1): 19-34.
[29]
Flower R. Steroidal antiinflammatory drugs as inhibitors of phospholipase A2. Adv Prostaglandin Thromboxane Res 1978; 3: 105-12.
[30]
Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med 2005; 353(16): 1711-23.
[31]
Buckenhueskes HJ. Industrial quality control. In: Berger RG, Ed. Flavours and Fragrances: Chemistry, Bioprocessing and Sustainability. Berlin: Springer 2007; pp. 303-12.
[32]
Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialogues Clin Neurosci 2007; 9(4): 413-30.
[33]
Punyamurthula NS, Hingorani T, Adelli G, et al. Controlled release tablet formulation containing natural (9)-tetrahydrocannabinol. Drug Dev Ind Pharm 2016; 42(7): 1158-64.
[34]
Thomas BF, Pollard GT. Preparation and distribution of Cannabis and Cannabis-derived dosage formulations for investigational and therapeutic use in the United States. Front Pharmacol 2016; 7(285): 285.
[35]
Fugh-Berman A, Wood S, Kogan M, et al. An introduction to the biochemistry & pharmacology of medical Cannabis 2016. Government of the District of Columbia. [Avaliable at:. doh.dc.gov/sites/default/files/dc/sites/doh/publi caton/attachments/Medical%20Cannabis%20An%20Introduction%20to%20the%20Biochemistry%20and%20Pharmacology.pdf [Accessed on: Jan 10, 2019].
[36]
Hornby AP, Hornby AP. Hayley’s Comet II CA2859934 2014.
[37]
Hornby AP. Hornby AP Hayley’s Comet CA2737447A1. 2011.
[38]
Tianrui C, Jingyue H. Anti-hepatitis medicine. CN105963356A 2016.
[39]
Zhang K, Liu J, Sun H. Hemp extract with antisensitive moisturizing effect and application thereof. CN105998195A 2016.
[40]
Tianrui C, Jingyue H. Application of a Cannabis extract in the preparation of a medicament for treating gouty arthritis. CN106074493A 2016.
[41]
Wallace HW. Method of relieving analgesia and Reducing inflamation using a Cannabinoid delivery. US6,949,582 2005.
[42]
Lansky EP. Pharmaceutical and cosmeceutical compositions containing cannabis flower and seed extracts. WO2010150245A1 2010.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 4
Year: 2019
Page: [256 - 267]
Pages: 12
DOI: 10.2174/1872208313666190618124345
Price: $58

Article Metrics

PDF: 8